Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

177 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force "Dermatology for Cancer Patients" International Study.
Sollena P, Vasiliki N, Kotteas E, Stratigos AJ, Fattore D, Orlandi A, Mannino M, Di Pumpo M, Fida M, Starace M, Apalla Z, Romano MC, Riganti J, Segura S, Martinez AF, Fabbrocini G, Sibaud V, Peris K, On Behalf Of The Eadv Task Force Dermatology For Cancer Patients. Sollena P, et al. Among authors: sibaud v. Cancers (Basel). 2023 Jul 18;15(14):3658. doi: 10.3390/cancers15143658. Cancers (Basel). 2023. PMID: 37509319 Free PMC article.
Drug reactions with eosinophilia and systemic symptoms induced by immune checkpoint inhibitors: an international cohort of 13 cases.
Ingen-Housz-Oro S, Milpied B, Bensaid B, Elshot Y, Brüggen MC, Starace M, Kaffenberger BH, Carrera C, Pham-Ledard A, Freites-Martinez A, Sanchez-Pena P, Lebrun-Vignes B, French LE, Sibaud V. Ingen-Housz-Oro S, et al. Among authors: sibaud v. Melanoma Res. 2023 Apr 1;33(2):155-158. doi: 10.1097/CMR.0000000000000877. Epub 2023 Feb 6. Melanoma Res. 2023. PMID: 36749114
Autoimmune Skin Diseases and Immune Checkpoint Inhibitors.
Fattore D, Potestio L, Genco L, Pages C, Ortiz A, Fabbrocini G, Sibaud V. Fattore D, et al. Among authors: sibaud v. Crit Rev Immunol. 2022;42(3):11-22. doi: 10.1615/CritRevImmunol.2023047032. Crit Rev Immunol. 2022. PMID: 37017623 Review.
The urgent need of dermatologists for cancer patients in Italy.
Fattore D, Fabbrocini G, Sibaud V, Sollena P. Fattore D, et al. Among authors: sibaud v. Ital J Dermatol Venerol. 2023 Jun;158(3):274-275. doi: 10.23736/S2784-8671.23.07531-X. Epub 2023 May 10. Ital J Dermatol Venerol. 2023. PMID: 37162245 No abstract available.
Use of omalizumab is associated with improvement of pruritic skin disorders induced by immune checkpoint inhibitors: A retrospective cohort from the European Task Force of Dermatology for Cancer patients.
Alamon-Reig F, Bosch-Amate X, Giavedoni P, Nikolaou V, Mangas C, Apalla Z, Mayor A, Oikonomou C, Starace M, Sibaud V, Carrera C. Alamon-Reig F, et al. Among authors: sibaud v. J Am Acad Dermatol. 2024 Feb;90(2):429-432. doi: 10.1016/j.jaad.2023.10.012. Epub 2023 Oct 14. J Am Acad Dermatol. 2024. PMID: 37844688 No abstract available.
Detection of novel therapies using a multi-national, multi-institutional registry of cutaneous immune-related adverse events and management.
Mital R, Otto TS, Savu A, Baumrin E, Cardones AR, Carlesimo M, Caro G, Freites-Martinez A, Hirner JP, Markova A, McLellan BN, Rossi A, Sauder MB, Seminario-Vidal L, Sibaud V, Owen DH, Dulmage BO, Chen ST, Kaffenberger BH. Mital R, et al. Among authors: sibaud v. Int J Dermatol. 2023 Aug;62(8):1020-1025. doi: 10.1111/ijd.16714. Epub 2023 May 19. Int J Dermatol. 2023. PMID: 37203799
PATEO syndrome.
Lacroix N, Anghel D, Sibaud V. Lacroix N, et al. Among authors: sibaud v. Ann Dermatol Venereol. 2024 Apr 27;151(2):103267. doi: 10.1016/j.annder.2024.103267. Online ahead of print. Ann Dermatol Venereol. 2024. PMID: 38678768 No abstract available.
177 results